目的探讨帕金森病伴可能快速眼动睡眠障碍患者的临床特点。方法收集2017—2019年在复旦大学附属华东医院神经内科门诊就诊的47例帕金森病患者的临床资料,使用帕金森病统一评定量表3.0版和Hoehn&Yahr(H-Y)分级评定PD患者症状严重程度...目的探讨帕金森病伴可能快速眼动睡眠障碍患者的临床特点。方法收集2017—2019年在复旦大学附属华东医院神经内科门诊就诊的47例帕金森病患者的临床资料,使用帕金森病统一评定量表3.0版和Hoehn&Yahr(H-Y)分级评定PD患者症状严重程度,梅奥睡眠问卷评估患者是否伴可能快速眼动睡眠障碍。结果根据伴或不伴可能快速眼动睡眠障碍,47例PD患者分为2组,PD伴可能快速眼动睡眠障碍患者31例(PD-pRBD组,66%),帕金森不伴可能快速眼动睡眠障碍患者(PD-npRBD组)16例(34%)。2组性别、年龄、发病年龄、是否服用多巴胺受体激动剂、H-Y分级、UPDRSⅡ及UPDRSⅢ评分比较差异无统计学意义(P>0.05);但帕金森伴可能快速眼动睡眠障碍患者的病程相对较长(76.84±51.41 vs41.25±39.14,P<0.05),精神、行为和情绪方面的UPDRSⅠ评分有明显差异(3.65±1.80 vs 2.19±1.68,P<0.05)。2组震颤、强直、延髓功能障碍(呛咳、流涎)和步态评分占UPDRSⅢ评分比例差异无统计学意义(P>0.05),但2组运动缓慢评分占UPDRSⅢ评分的比例(39.13±7.34 vs 46.06±6.71)差异有统计学意义(P=0.003),躯体/肢体症状比例(0.68±0.22 vs 0.54±0.24,P=0.048)差异有统计学意义(P=0.048),PD-pRBD患者有更高的比值。29%的可能快速眼动睡眠障碍患者有跌倒经历,而不伴可能快速眼动睡眠障碍组发生跌倒的患者比例只有12%,2组间跌倒发生率有显著性差异(P=0.045)。结论 PD-pRBD患者病程更长,多伴精神、行为和情绪异常,运动更趋于缓慢,容易发生跌倒和出现躯体体征。展开更多
The immunocytes microglia in the central nervous system （CNS） were reported to play a crucial role in neurodegeneration. As a member of P2 receptors family, purinoceptor P2Y6 has attracted much attention recently. P...The immunocytes microglia in the central nervous system （CNS） were reported to play a crucial role in neurodegeneration. As a member of P2 receptors family, purinoceptor P2Y6 has attracted much attention recently. Previous studies showed that purinoceptor P2Y6 mainly contributed to microglia activation and their later phagocytosis in CNS, while in immune system, it participated in the secretion of interleukin （IL）-8 from monocytes and macrocytes. So there raises a question： whether purinoceptor P2Y6 also takes part in neuroinflammation？ Thus, this review mainly concerns about the properties and roles of purinoceptor P2Y6, including （1） structure of purinoceptor P2Y6; （2） distribution and properties of purinoceptor P2Y6; （3） relationships between purinoceptor P2Y6 and microglia; （4） relationships between purinoceptor P2Y6 and immunoinflammation. It＇s proposed that purinoceptor P2Y6 may play a role in neuroinflammation in CNS, although further research is still required.展开更多
文摘目的探讨帕金森病伴可能快速眼动睡眠障碍患者的临床特点。方法收集2017—2019年在复旦大学附属华东医院神经内科门诊就诊的47例帕金森病患者的临床资料,使用帕金森病统一评定量表3.0版和Hoehn&Yahr(H-Y)分级评定PD患者症状严重程度,梅奥睡眠问卷评估患者是否伴可能快速眼动睡眠障碍。结果根据伴或不伴可能快速眼动睡眠障碍,47例PD患者分为2组,PD伴可能快速眼动睡眠障碍患者31例(PD-pRBD组,66%),帕金森不伴可能快速眼动睡眠障碍患者(PD-npRBD组)16例(34%)。2组性别、年龄、发病年龄、是否服用多巴胺受体激动剂、H-Y分级、UPDRSⅡ及UPDRSⅢ评分比较差异无统计学意义(P>0.05);但帕金森伴可能快速眼动睡眠障碍患者的病程相对较长(76.84±51.41 vs41.25±39.14,P<0.05),精神、行为和情绪方面的UPDRSⅠ评分有明显差异(3.65±1.80 vs 2.19±1.68,P<0.05)。2组震颤、强直、延髓功能障碍(呛咳、流涎)和步态评分占UPDRSⅢ评分比例差异无统计学意义(P>0.05),但2组运动缓慢评分占UPDRSⅢ评分的比例(39.13±7.34 vs 46.06±6.71)差异有统计学意义(P=0.003),躯体/肢体症状比例(0.68±0.22 vs 0.54±0.24,P=0.048)差异有统计学意义(P=0.048),PD-pRBD患者有更高的比值。29%的可能快速眼动睡眠障碍患者有跌倒经历,而不伴可能快速眼动睡眠障碍组发生跌倒的患者比例只有12%,2组间跌倒发生率有显著性差异(P=0.045)。结论 PD-pRBD患者病程更长,多伴精神、行为和情绪异常,运动更趋于缓慢,容易发生跌倒和出现躯体体征。
基金supported by the Key Scientific Research Innovation Program of Shanghai Municipal Education Commission,China (No.082260)
文摘The immunocytes microglia in the central nervous system （CNS） were reported to play a crucial role in neurodegeneration. As a member of P2 receptors family, purinoceptor P2Y6 has attracted much attention recently. Previous studies showed that purinoceptor P2Y6 mainly contributed to microglia activation and their later phagocytosis in CNS, while in immune system, it participated in the secretion of interleukin （IL）-8 from monocytes and macrocytes. So there raises a question： whether purinoceptor P2Y6 also takes part in neuroinflammation？ Thus, this review mainly concerns about the properties and roles of purinoceptor P2Y6, including （1） structure of purinoceptor P2Y6; （2） distribution and properties of purinoceptor P2Y6; （3） relationships between purinoceptor P2Y6 and microglia; （4） relationships between purinoceptor P2Y6 and immunoinflammation. It＇s proposed that purinoceptor P2Y6 may play a role in neuroinflammation in CNS, although further research is still required.
